Pancreatic Cancer with Peritoneal Micrometastasis
Treatment Landscape, HK vs SG Specialist Comparison & Action Plan · July 2026
📊 Research compiled July 2026
🏥 HK ↔ SG comparison
🔬 20+ sources cited
⚠️ MEDICAL DISCLAIMER
This report is for informational purposes only and does NOT constitute medical advice. The patient must consult with qualified oncologists for all diagnosis and treatment decisions. Every case is unique and general statistics do not predict individual outcomes. All treatment decisions should be made with the patient's medical team.
Quick Summary — Key Takeaways
- The condition: Pancreatic ductal adenocarcinoma (PDAC) with peritoneal micrometastasis. The belly button lump is likely a Sister Mary Joseph nodule — a known sign of intra-abdominal cancer spread to the umbilical area.
- "Micrometastatic" is potentially advantageous: Deposits are still microscopic, not yet large visible tumors. This may mean earlier-stage peritoneal spread, which could respond better to treatment.
- 2025-2026 breakthroughs: KRAS inhibitors (daraxonrasib) received FDA Breakthrough Therapy designation. A patient with peritoneal metastases achieved confirmed complete response in clinical trials.
- Singapore's NCCS SPRinT team is one of Asia's most experienced peritoneal cancer centers (500+ CRS/HIPEC procedures since 2001) and offers PIPAC — a newer, less invasive treatment specifically targeting peritoneal disease.
- Most actionable step now: Get molecular profiling (KRAS mutation status, BRCA status) — this determines eligibility for breakthrough therapies and clinical trials.
1 · Understanding the Condition
What is Pancreatic Cancer with Peritoneal Micrometastasis?
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. The peritoneum — the membrane lining the abdominal cavity — is the second most common site of metastasis in pancreatic cancer. Up to 50% of patients who undergo curative-intent surgery eventually develop peritoneal metastasis. source
"Micrometastatic" means the cancer deposits on the peritoneum are microscopic — too small to be seen as large tumors on imaging. This is potentially an earlier stage of peritoneal spread compared to gross peritoneal carcinomatosis (where visible tumor nodules cover the abdominal lining).
The Sister Mary Joseph Nodule
The lump at the belly button is likely a Sister Mary Joseph (SMJ) nodule — named after a Mayo Clinic nurse who first identified the sign. It occurs when cancer cells spread from the abdominal cavity to the umbilical area, either through direct extension, lymphatic spread, or vascular channels.
Important context on prognosis: Older medical literature reports poor outcomes for SMJ nodules (mean survival ~10 months across all cancer types). For pancreatic cancer specifically, older studies cited survival of less than 3 months.
However, these figures are from historical data before modern treatments existed. Current therapies — FOLFIRINOX, targeted therapy (KRAS inhibitors), PIPAC, and combination approaches — have significantly improved outcomes. Early/micrometastatic stage may have better prognosis than these older statistics suggest.
source ·
source
Why Pancreatic Cancer is Challenging
- Often diagnosed late due to vague symptoms (abdominal pain, weight loss, jaundice)
- Tumor microenvironment is immunosuppressive — limits immunotherapy effectiveness
- >90% of tumors carry KRAS mutations — long considered "undruggable" until recent breakthroughs
- Peritoneal spread creates a protective environment for cancer cells (peritoneal-plasma barrier limits IV chemotherapy penetration)
2 · Treatment Landscape
FACTS in normal text. SPECULATION in italics. Evidence levels are indicated for each treatment.
1. Systemic Chemotherapy ✅ Standard of Care
The backbone of treatment for metastatic pancreatic cancer. Two primary first-line regimens:
| Regimen | Key Data | Profile |
|---|
| FOLFIRINOX (5-FU, leucovorin, irinotecan, oxaliplatin) | Median PFS ~6.3 months (classical PDAC subtype). Higher response rates. source | More aggressive, higher side effects. For fit patients. |
| Gemcitabine + Nab-Paclitaxel (GnP) | Median PFS ~5.4-5.5 months. source | Better tolerated. Widely used. For less fit patients. |
| NALIRIFOX (liposomal irinotecan + 5-FU + oxaliplatin) | Newer regimen. Meta-analysis ongoing. source | Alternative first-line option. |
Choice depends on patient fitness, molecular subtype (basal-like vs classical), and oncologist preference. Both available in HK and SG.
2. CRS + HIPEC ❓ Emerging / Controversial for PDAC
Cytoreductive Surgery (CRS) surgically removes all visible peritoneal deposits. HIPEC (Hyperthermic Intraperitoneal Chemotherapy) then circulates heated chemotherapy directly in the abdominal cavity during surgery.
- Established for colorectal, ovarian, and appendiceal peritoneal cancers
- Controversial but emerging for pancreatic cancer — no broad consensus yet
- For highly selected patients only: low Peritoneal Cancer Index (PCI), good performance status
- Key study: patients achieving complete cytoreduction had 17 months median PFS vs 5 months with incomplete removal source
- Without treatment, median survival for pancreatic peritoneal metastasis: 6-11 months source
For micrometastatic disease specifically, CRS+HIPEC may be more feasible than for gross carcinomatosis, as complete cytoreduction is more achievable when deposits are small.
3. PIPAC 🔬 Innovative / Less Invasive
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) — a newer, less invasive alternative to HIPEC:
- Uses laparoscopic keyhole approach (no open surgery)
- Chemotherapy delivered as pressurized aerosol spray into peritoneal cavity
- Better tissue penetration than IV chemo for peritoneal deposits
- Can be repeated multiple times (typically every 6 weeks)
- Can be combined with systemic chemotherapy
- Case report: PDAC patient treated with systemic chemo + PIPAC showed promising results source
Why PIPAC matters for this case: For micrometastatic peritoneal disease, PIPAC may be particularly suitable — it targets exactly the peritoneal surface where microscopic deposits reside, with far less morbidity than HIPEC. NCCS Singapore offers this procedure.
4. Targeted Therapy — KRAS Inhibitors 🚀 2025-2026 Breakthrough
The most significant advance in pancreatic cancer treatment in decades:
- >90% of pancreatic tumors carry KRAS mutations — long considered "undruggable" source
- Daraxonrasib (RMC-6236):
- FDA Breakthrough Therapy designation — June 2025 source
- Phase 3 RASOLUTE 302 trial completed enrollment in metastatic PDAC source
- A stage IV PDAC patient with liver AND peritoneal metastases achieved confirmed complete response after 6 cycles (after conventional therapies failed) source
- 20% partial response rate, 87% disease control rate in clinical trial source
- Setidegrasib: Phase 1 trial results published March 2026 in NEJM (MSKCC) source
- PARP Inhibitors (Olaparib): FDA-approved for BRCA-mutated PDAC
Critical action: The patient's tumor MUST be tested for KRAS mutation status and BRCA status. This determines eligibility for these breakthrough therapies and ongoing clinical trials. If not yet done, this is the #1 priority.
5. Immunotherapy 🔬 Investigational
- CD40 pathway targeting + chemotherapy + checkpoint inhibitors (CRI trial, Dr. Vonderheide) source
- Research notes lower immunogenicity in peritoneal recurrences specifically — a challenge for this site source
- mRNA vaccines, peptide vaccines, dendritic cell vaccines under investigation
- Researchers testing whether altering the tumor environment first (chemo, radiation, vaccines) makes immunotherapy work better source
Immunotherapy is not yet standard for PDAC but clinical trials are expanding rapidly. Singapore may have trials not available in Hong Kong.
6. Clinical Trials 🔬 Access Pathway
For a case like this, clinical trials may offer access to treatments not yet commercially available:
- NCI lists active pancreatic cancer trials: cancer.gov clinical trials
- KRAS-targeted trials are the fastest-growing area
- Combination immunotherapy + chemo trials ongoing
- Both Singapore (NCCS, NCIS) and Hong Kong (HKU, CUHK) run clinical trials — eligibility depends on molecular profile
3 · Singapore: Specialists & Centers
NCCS / SGH — SPRinT Team ⭐ Top Recommendation
Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT)
National Cancer Centre Singapore + Singapore General Hospital
- Performing CRS + HIPEC since 2001 — one of the most extensive experience in Asia
- 500+ CRS/HIPEC procedures — outcomes comparable to international high-volume centers source
- Offers PIPAC — one of few centers in Asia source
- Weekly multidisciplinary tumor board meetings source
Key Specialists:
| Doctor | Role | Relevance |
|---|
| A/Prof Claramae Chia | Senior Consultant, SPRinT | Surgical oncologist specializing in peritoneal disease — profile |
| Dr Tham Chee Kian | Deputy Chairman, Medical Oncology | Treats pancreatic + peritoneal cancers — profile |
| Dr Matthew Ng Chau Hsien | Head of GI Oncology, NCCS | Leads GI cancers service line — profile |
| Dr Kennedy Ng Yao Yi | Medical Oncology | Pancreatic cancer researcher, published on neoadjuvant therapy — profile |
NCIS — National University Cancer Institute Singapore
- Also performs CRS/HIPEC for peritoneal surface malignancies
- Has PIPAC research program (NCT03172416) — investigating PIPAC as palliative treatment for advanced cancers with peritoneal disease source
Private Sector Options
| Center | Notes |
|---|
| OncoCare | Private oncology with pancreatic cancer specialists. Part of HMG + OncoCare Pan-Asian network for cross-border second opinions. link |
| Mount Elizabeth Hospitals | Private hospital with pancreatic cancer team. Dr Tan Yu-Meng noted. link |
| Parkway East Hospital | Pancreatic cancer specialists. link |
| Gleneagles Hospital | Pancreatic cancer team. link |
| Nexus Surgical | Dr Ho Choon Kiat — hepatobiliary & pancreatic surgeon. link |
4 · Hong Kong: Specialists & Centers
Public Hospitals
Queen Mary Hospital (HKU) ⭐ Premier HK Center
- Division of Hepatobiliary & Pancreatic Surgery, Department of Surgery, HKU — global reputation for HBP surgery source
- Department of Clinical Oncology (HKU) — integrated clinical and academic unit source
- ESMO-accredited integrated oncology & palliative care center source
- Contact: (+852) 2255 4352
- Note: Prof. Chung-mau Lo, former Chair of HBP Surgery at HKU, is now HK's Secretary for Health — signals government prioritization of HBP expertise source
Prince of Wales Hospital (CUHK)
- Department of Clinical Oncology — academic and clinical unit source
- Serves 1.8M population in New Territories East Cluster
- Has Hepatobiliary & Pancreatic Surgery division source
Private Sector
| Center | Notes |
|---|
| HKIOC (Hong Kong Integrated Oncology Centre) | Multi-specialty oncology team. link |
| HEAL Medical | Boutique oncology centre, pancreatic cancer treatment. Central + TST locations. link |
5 · Hong Kong vs Singapore — Side-by-Side
| Dimension | 🇭🇰 Hong Kong | 🇸🇬 Singapore |
|---|
| HIPEC Experience |
Queen Mary Hospital has HBP surgery expertise; specific CRS/HIPEC volume for PDAC not widely reported |
NCCS SPRinT: 500+ CRS/HIPEC since 2001 — one of Asia's most experienced. Clear advantage for peritoneal disease. |
| PIPAC Availability |
Not widely available in HK public system |
Available at NCCS + NCIS — one of few centers in Asia offering PIPAC |
| Clinical Trials |
HKU and CUHK run trials; KRAS inhibitor trial access unclear |
NCCS + NCIS run active trials; KRAS-targeted trials potentially available. Check current enrollment. |
| Multidisciplinary Care |
QMH has established MDT for oncology |
NCCS has dedicated weekly peritoneal tumor board (SPRinT) |
| Wait Times (Public) |
HK public hospital wait times can be long for non-emergency oncology referrals |
NCCS international patient liaison can expedite; private sector fast access |
| Cost (Public) |
Covered for HK residents under HA system |
International patient rates apply; subsidies for SG residents/PRs only |
| Cost (Private) |
HK private oncology — comparable to SG private |
SG private — similar range; OncoCare, Mount Elizabeth etc. |
| Language |
Cantonese, English, Mandarin |
English, Mandarin, Malay — all doctors fluent in English |
| Travel |
Patient is HK-based |
~4 hour flight HK ↔ SG. Treatment may require multiple visits for PIPAC/CRS |
| Cross-Border Support |
HK eHealth system for medical record sharing (patient-authorized) source |
HMG + OncoCare Pan-Asian Cooperation Agreement for cross-border cancer second opinions source |
Bottom line: Singapore has a clear advantage in peritoneal-specific expertise (SPRinT team, PIPAC, 500+ HIPEC procedures). Hong Kong has excellent HBP surgical expertise at Queen Mary Hospital. The ideal path may be: continue systemic chemo in HK, get SG second opinion from NCCS SPRinT team, evaluate PIPAC eligibility, and explore clinical trial options in both cities.
6 · What You Can Do — Action Plan
As someone based in Singapore wanting to help a friend in Hong Kong, here are the concrete steps:
-
Help collect complete medical records
Your friend needs to gather: imaging scans (CT/MRI/PET-CT), pathology/biopsy reports, blood work (especially CA 19-9 tumor marker), current treatment history, and any existing treatment plan. Hong Kong's eHealth system allows patient-authorized record sharing. source
-
Ensure molecular profiling is done
This is the #1 medical priority. The tumor must be tested for:
- KRAS mutation status — determines eligibility for daraxonrasib and other KRAS inhibitor trials
- BRCA 1/2 status — determines eligibility for PARP inhibitors (olaparib)
- PD-L1 status — relevant for immunotherapy options
- Microsatellite instability (MSI) — rare in PDAC but affects treatment choice
If the HK oncologist hasn't ordered this, it needs to be requested urgently. This testing is available in both HK and SG.
-
Arrange a Singapore second opinion
Two pathways:
- NCCS International Patient Liaison — contact NCCS directly for international patient second opinion. Records can be sent electronically. NCCS doctors directory
- OncoCare (private) — part of HMG + OncoCare Pan-Asian network for cross-border cancer second opinions. Faster access. link
Request evaluation specifically from the SPRinT team for peritoneal disease assessment.
-
Ask about PIPAC specifically
For micrometastatic peritoneal disease, PIPAC may be ideal — it targets exactly the peritoneal surface with less invasiveness than HIPEC. NCCS Singapore offers this. Ask the NCCS team whether the patient's peritoneal disease burden is suitable for PIPAC.
-
Explore clinical trials in both cities
Search: NCI clinical trials database — filter by KRAS trials, Singapore/Hong Kong locations. Ask both HK and SG oncologists about currently enrolling trials.
-
Check insurance coverage for cross-border treatment
Verify whether your friend's insurance covers treatment in Singapore. Some HK insurance policies cover overseas treatment. NCCS international patient office can provide cost estimates.
-
Consider logistics if SG treatment is recommended
SG ↔ HK is a 4-hour flight. PIPAC requires repeated visits (typically every 6 weeks). CRS/HIPEC requires a single longer stay (2-3 weeks in SG). Plan accommodation and support accordingly.
7 · Questions to Ask the Oncologist
Prepared questions for your friend to ask their HK doctor, and for the SG second opinion:
For the current HK oncologist:
"Has the tumor been tested for KRAS mutation, BRCA status, and PD-L1? If not, can this be ordered now?"
"What is the current Peritoneal Cancer Index (PCI) score based on imaging?"
"Is the disease truly micrometastatic only, or are there visible peritoneal deposits on CT/PET-CT?"
"What chemotherapy regimen do you recommend and why? FOLFIRINOX or Gemcitabine/Nab-Paclitaxel?"
"Are there any clinical trials available in Hong Kong that would be suitable for this case?"
"Would you support a second opinion from Singapore's NCCS SPRinT team for peritoneal disease evaluation?"
"What is the current CA 19-9 level and how is it trending?"
For the NCCS Singapore second opinion:
"Based on the imaging and pathology, is this case suitable for PIPAC?"
"Would CRS + HIPEC be considered for this patient, or is systemic therapy the better first approach?"
"Are there any clinical trials at NCCS or NCIS that this patient would be eligible for?"
"If PIPAC is recommended, how many sessions would be expected, and what is the treatment schedule?"
"Can PIPAC be combined with systemic chemotherapy simultaneously?"
"What are the realistic outcomes for this specific presentation (micrometastatic PDAC with SMJ nodule)?"
"What is the estimated cost for international patient treatment at NCCS?"
8 · Key Sources & References
- Management of Peritoneal Metastasis in PDAC — MDPI Dermatol Ther
- Sister Mary Joseph Nodule as Initial Presentation of Pancreatic Adenocarcinoma — PMC
- SMJ Nodule Case Report & Literature Review — PMC
- CRS + HIPEC for Pancreatic Cancer with Peritoneal Metastasis — GI Oncology Now
- Oncologic Outcomes of CRS and HIPEC for PDAC — Annals of Surgical Oncology
- CRS/HIPEC Review in GI Cancer — Frontiers in Oncology Reviews
- mFOLFIRINOX vs Gem/Nab-Paclitaxel — ASCO Post
- NALIRIFOX vs FOLFIRINOX vs Gem/Nab-Paclitaxel Meta-Analysis — JAMA Network Open
- NCCS SPRinT Clinical Services — NCCS
- NCCS PIPAC — NCCS
- Peritoneal Surface Oncology in Singapore — PMC/NIH
- PIPAC for Pancreatic Peritoneal Metastases Case Report — PMC
- KRAS Inhibitor Breakthrough — Daraxonrasib — MSKCC
- Setidegrasib Phase 1 Trial — MSKCC
- KRAS Drugging Review — Cancer Biology & Medicine
- 2026 Pancreatic Cancer Treatment Advances — HOncology
- Immunotherapy in Pancreatic Cancer — Cancer Research Institute
- Peritoneal Recurrence Immunogenicity — PMC
- NCI Clinical Trials — cancer.gov
- HMG + OncoCare Pan-Asian Agreement — Rutland Herald
- HK eHealth Cross-Border Records — HK Gov
- Queen Mary Hospital Oncology — QMH
- HKU HBP Surgery — HKU Surgery
- CUHK Clinical Oncology — CUHK
⚠️ MEDICAL DISCLAIMER
This report was compiled from publicly available medical literature and institutional websites as of July 2026. It is for informational purposes only and does NOT constitute medical advice, diagnosis, or treatment recommendations. The patient must consult with qualified oncologists for all medical decisions. Every case is unique. General statistics cited here do not predict individual outcomes. Treatment availability, clinical trial enrollment, and institutional details may change — verify directly with the relevant institutions before making any decisions.